IPSEN
SpecialtyIPSEN is a specialty pharmaceutical company focused on Oncology, Gastroenterology, Neurology. Key products include BYLVAY.
FDA Novel Drug Designations
(2021-2024)IPSEN at a Glance
- Leading 5 drug targets across portfolio
- Fast trial execution (28 months median completion)
IPSEN's Key Drugs
IPSEN's core commercial portfolio centers on BYLVAY, IQIRVO, ONIVYDE, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
Progressive Familial Intrahepatic Cholestasis
Primary Biliary Cholangitis
Pancreatic Adenocarcinoma
Fibrodysplasia Ossificans Progressiva
IPSEN's Recent FDA Approvals
New NDA/BLA approvals for IPSEN over the last two years — novel drugs only, excluding generics and label supplements.
IPSEN's Therapeutic Areas
IPSEN's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology, across 1 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IPSEN's Top Competitors
IPSEN's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and EMD SERONO. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IPSEN Pipeline Snapshot
IPSEN has 50 active clinical programs from ClinicalTrials.gov — 13 Phase 3, 19 Phase 2 and 18 Phase 1.
Phase 3 Readout Calendar Pro
4 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 32/47 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges